Search Results - "ROUSSO, P"

  • Showing 1 - 8 results of 8
Refine Results
  1. 1

    Icatibant has no impact on renal function in healthy subjects by Rousso, P., Nguyen, M., Perrin, Y., Buclin, T., Décosterd, L. A., Nussberger, J., Appenzeller, M., Jaquet, F., Brunner‐Ferber, F., Rosenkranz, B., Knolle, J., Biollaz, J.

    Published in Clinical pharmacology and therapeutics (01-02-2004)
    “…The role of bradykinin (BK) in renal regulations is still controversial. To elucidate whether Icatibant, a potent BK antagonist on B2 receptors, can interfere…”
    Get full text
    Journal Article
  2. 2

    Bioavailability of repeated oral administration of MDL 100,240, a dual inhibitor of angiotensin-converting enzyme and neutral endopeptidase in healthy volunteers by ROUSSO, P, BUCLIN, T, NUSSBERGER, J, BRUNNER-FERBER, F, BRUNNER, H. R, BIOLLAZ, J

    Published in European journal of clinical pharmacology (01-01-2000)
    “…MDL 100,240 (pyrido[2,1-a] [2]benzazepine-4-carboxylic acid,7-[[2-(acetylthio)-1-oxo-3-phenylpropyl]amino]-1,2,3,4,6,7,8, 12b-octahydro-6-oxo,…”
    Get full text
    Journal Article
  3. 3

    Pharmacokinetic and pharmacodynamic profile of icatibant by Perrin, Y., Nguyen, M. T., Rousso, P., Buclin, T., Rochat, B., Decosterd, L., Appenzeller, M., Jaquet, F., Brunner‐Ferber, F., Rosenkranz, B., Knolle, J., Biollaz, J.

    Published in Clinical pharmacology and therapeutics (01-02-2004)
    “…Icatibant, a potent bradykinin (BK) antagonist specific for B2 receptors, was administered i.v. to 18 healthy males to assess its safety, pharmacokinetic, and…”
    Get full text
    Journal Article
  4. 4

    Effects of a dual inhibitor of angiotensin converting enzyme and neutral endopeptidase, MDL 100 240, on endocrine and renal functions in healthy volunteers by Rousso, Philippe, Buclin, Thierry, Nussberger, Jürg, Décosterd, Laurent A, La Roche, Salome D, Brunner-Ferber, Françoise, Brunner, Hans R, Biollaz, Jérôme

    Published in Journal of hypertension (01-03-1999)
    “…OBJECTIVETo investigate the endocrine and renal effects of the dual inhibitor of angiotensin converting enzyme and neutral endopeptidase, MDL 100 240. DESIGNA…”
    Get full text
    Journal Article
  5. 5
  6. 6

    Specific determination of PAH and its N-acetyl metabolite by HPLC increases the accuracy and precision of PAH clearance measurements by Decosterd, L A, Bélaz, N, Appenzeller, M, Maghraoui, A, Rousso, P, Buclin, T, Biollaz, J

    Published in Renal failure (01-01-1998)
    “…PAH (N-(4-aminobenzoyl)-glycin) clearance measurements have been used for 50 years in clinical research for the determination of renal plasma flow. The…”
    Get more information
    Journal Article
  7. 7

    Power plant simulation using a computer aided test station by Lew, P., Rousso, P., Petrescu, D.

    “…With the advent of the ACCLAIM series power plant controller/monitors, it has become necessary to produce more elaborate and more sophisticated tests to assure…”
    Get full text
    Conference Proceeding
  8. 8

    A microprocessor based power plant monitor and control system having total rectifier diagnostic capability by Rousso, P., Lew, P., Gauthier, R., Petrescu, D., Cobo, J., Vermette, Y.

    “…The ACCLAIM is a microprocessor-based power-plant controller designed to provide the user with the primary features of statistics gathering and plant control…”
    Get full text
    Conference Proceeding